LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Publisher: Elsevier
Languages: English
Types: Article
Subjects:
Background: The faecal calprotectin (FC) test is a non-invasive marker for gastrointestinal inflammation. \ud Aim: To determine whether higher FC levels in individuals with quiescent Crohn’s disease are associated with clinical relapse over the ensuing 12 months.

\ud Methods: A single centre prospective study was undertaken in Crohn's disease patients in clinical remission attending for routine review. The receiver operating characteristic (ROC) curve for the primary endpoint of clinical relapse by 12 months, based on FC at baseline, was calculated. Kaplan-Meier curves of time to relapse were based on the resulting optimal FC cutoff for predicting relapse.

\ud Results: Of 97 patients recruited, 92 were either followed up for 12 months without relapsing, or reached the primary endpoint within that period. Of these, 10 (11%) had relapsed by 12 months. The median FC was lower for non-relapsers, 96µg/g (IQR 39-237), than for relapsers, 414µg/g (IQR 259-590), (p=0.005). The area under the ROC curve to predict relapse using FC was 77.4%. An optimal cutoff FC value of 240µg/g to predict relapse of quiescent Crohn’s had sensitivity of 80.0% and specificity of 74.4%. Negative predictive value was 96.8% and positive predictive value was 27.6%. FC≥240μg/g was associated with likelihood of relapse 5.7 (95% CI 1.9-17.3) times higher within 2.3 years than lower values (p=0.002).

\ud Conclusions: In this prospective dataset, FC appears to be a useful, non-invasive tool to help identify quiescent Crohn’s disease patients at a low risk of relapse over the ensuing 12 months. FC of 240µg/g was the optimal cutoff in this cohort.

  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein in patients with inflammatory bowel disease. Scand J Gastroenterol 1999;34:50-4.
    • 2. Roseth AG, Aadland E, Jahnsen J et al. Assessment of disease activity in Ulcerative Colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997;58:176-180
    • 3. Sipponen T, Saviahti E Kohlo KL et al. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflam Bowel Dis. 2008;14:40-46
    • 4. Tibble JA, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000;47:506-13.
    • 5. Sutherland AD, Geary RB, Frizelle FA. Review of fecal biomarkers in inflammatory bowel disease. Dis Colon Rectum 2008; 51:1283-91
    • 6. Schoepfer AM, Trummler M, Seeholzer P, Seibold-Schmid B, Seibold F. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leucocytes, CRP and IBD antibodies. Inflamm Bowel Dis 2008;14:32-9
    • 7. Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis 2009;41:55-66
    • 8. Centre for Evidence-based purchasing. Value of Calprotectin in screening out Irritable Bowel Syndrome: Evidence Review. London: NHS Purchasing and Supply Agency, 2009: CEP09026
    • 9. Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 2004;39:1017-20.
    • 10. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos G J. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel disease: performance of fecal lactoferrin, calprotectin and PMN-elastase, CRP and clinical indices. Am J Gastroenterol 2008;103:162-169
    • 11. Jones J, Loftus EV, Panaccione R et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 2008;6:1218-24
    • 13. Tibble J.A, Sigthorsson G., Bridger S., Fagerhol M.K., Bjarnason I. Surrogate Markers of Intestinal Inflammation Are Predictive of Relapse in Patients With Inflammatory Bowel Disease. Gastroenterology 2000; 119: 15-22.
    • 14. Costa F, Mumolo MG, Ceccarelli Let al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005;54:364-368
    • 15. D'Inca R, Dal Pont E, Di Leo V et al. Can Calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol 2008;103:2007-2014
    • 16. Gisbert JP, Bermejo F, Perez-Calle JL et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis. 2009;15(8):1190-8.
    • 17. Garcia-Sanchez V, Iglesias-Flores E, Gonzalez R et al. Does Fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis? J Crohns Colitis 2010 4(2):144-52
    • 18. Kallel L, Ayadi I, Matri S et al. Fecal calprotectin is a predictive marker of replase in Crohn's disease involving the colon: a prospective study. European Journal of Gastroenterology & Hepatology 2010;22:340-345
    • 19. Laharie D, Mesli S, El Hajbi F et al. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study. Aliment Pharmacol Ther . 2011;34(4):462-9
    • 20. Mao R, Xiao YL, Gao X et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm. Bowel Dis.2012;18(10),1894-1899
    • 21. Best WR, Becktel JM, Singleton JW, Kern F Jr et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976; 70: 439-444
    • 22. Naismith GD, Smith LA, Barry SJE, Munro JI, Laird S, Rankin K, Morris AJ, Winter JW, Gaya DRG. A prospective single centre evaluation of the intra-individual variability of the faecal calprotectin test in quiescent Crohn's disease. Aliment Pharmacol Ther 2013;37:613-21
    • 23. Manz M, Burri E, Rothen C. et al. Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study. BMC Gastroenterol. 2012;12:5
    • 24. Van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010;341:c3369.
    • 26. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos G J. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel disease: performance of fecal lactoferrin, calprotectin and PMN-elastase, CRP and clinical indices. Am J Gastroenterol 2008;103:162-169
    • 27. Jones J, Loftus EV, Panaccione R et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 2008;6:1218-24
    • 28. Lamb CA, Mohiuddin MK, Gicquel J, et al. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease. Br J Surg 2009; 96: 663-74.
    • 29. Boschetti, G., D. Moussata, A-L.Charlois, B. Flourié, and S. Nancey. P314 Accuracy of fecal calprotectin in the assessment of post-operative endoscopic recurrence in patients with Crohn's disease. Journal of Crohn's and Colitis 7 (2013): S134-S135.
    • 30. Beltrán, B., E. Cerrillo, M. Iborra, I. Moret, F. Rausell, L. Tortosa, G. Bastida, M. Aguas, and P. Nos. "P172 Fecal calprotectin (FC) is a useful early predictive marker for postoperative recurrence in Crohn's disease (CD)." Journal of Crohn's and Colitis 6 (2012): S78
    • 31. Guidi, L, Marzo M, Andrisani G, Felice C, Pugliese D, De Vitis I, Papa A, Rapaccini GL, Forni F, Armuzzi A. P214 Faecal calprotectin assay after induction with antiTNF alpha agents in IBD patients: prediction of clinical response and mucosal healing at one year. Journal of Crohn's and Colitis 7 (2013): S95.
    • 32. Ferreiro, R., M. Barreiro-de Acosta, M. Otero, A. Lorenzo, C. Alonso, and J. E. Dominguez-Munoz. P109 Use of faecal calprotectin as predictor of relapse in patients under maintenance treatment with infliximab. Journal of Crohn's and Colitis 7 (2013): S52-S53.
    • 33. Molander, P, af Björkesten C. G, Mustonen, H, Haapamäki J, Vauhkonen M, Kolho et al. (2012). Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNF± blocking agents. Inflammatory bowel diseases, 18(11), 2011-2017
    • 34. D'Haens G, Ferrante M, Vermeire S, Baert F, Norman M, Moortgat L et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflammatory bowel diseases, 18(12):2218-24, 2012 Dec.
    • 35. Hanaway P, Roseth A Inflammatory biomarkers predict relapse in IBD. Gut 2005;54:1346-1347
    • 36. Pardi D S. Sandborn, W. J. Predicting relapse in patients with inflammatory bowel disease: what is the role of biomarkers?. Gut 2005 54(3), 321-322.
    • 37. Lemann M, Mary JY. Calprotectin and IBD. Gut 2005; 54:1349-1350
    • 38. Saverymuttu SH, Peters AM, Crofton ME 111 Indium autologous granulocytes in the detection of inflammatory bowel disease. Gut 1985; 26:955-960
    • 39. Primas, C, Frühwald G, Angelberger S, Allerstorfer D, Papay P, Eser A, Gratzer C et al. P381 Role of fecal calprotection in predicting ileocolonic endoscopic recurrence in postoperative Crohn's disease. Journal of Crohn's and Colitis 7 (2013): S162.
    • 40. Kennedy, N. A, Chang J, Guy MH, Smith T, Loh JT, Haunschmidt D, Muscat M et al. P250 Elevated faecal calprotectin predicts disease progression in Crohn's disease. Journal of Crohn's and Colitis 7 (2013): S109-S110.
    • 41. Louis, E, Mary, J Y, Vernier-Massouille, G, Grimaud J C, Bouhnik Y, Laharie D et al (2012). Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology, 142(1), 63-70
    • 42. De Suray, Nicolas, Julia Salleron, Gwenola Vernier-Massouille, Jean-Charles Grimaud, YoramBouhnik, David Laharie, Jean-Louis Dupas et al. "864 Close Monitoring of CRP and Fecal Calprotectin is Able to Predict Clinical Relapse in Patients With Crohn's Disease in Remission After Infliximab Withdrawal. a SubAnalysis of the Stori Study." Gastroenterology 142, no. 5 (2012): S-149.
    • 43. Cosnes, J., Cattan, S., Blain, A., Beaugerie, L., Carbonnel, F., Parc, R. and Gendre, J.- P. (2002), Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis, 8: 244-250
  • No related research data.
  • No similar publications.

Share - Bookmark

Download from

Cite this article